Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Antitussive refers to a drug class or therapeutic category of medications used to suppress or relieve cough. It is not a molecular target or receptor itself. Instead, drugs classified as antitussives achieve their therapeutic effect by interacting with multiple distinct molecular targets and pathways. These targets can include the mu-opioid receptor (e.g., codeine), NMDA receptor (e.g., dextromethorphan), voltage-gated sodium channels (e.g., benzonatate), and potentially others like kappa-opioid receptors, GABA-B receptors, tachykinin receptors, non-opioid (NOP-1) receptors, and sigma receptors. Therefore, 'Antitussive' describes a functional classification of drugs, not a specific biological entity amenable to direct targeting.
Antitussives, as a drug class, exert their therapeutic effect by suppressing the cough reflex. This is achieved through various distinct molecular mechanisms and targets, which depend on the specific agent within the class. Examples include modulation of mu-opioid receptors, NMDA receptors, or voltage-gated sodium channels to reduce the frequency or severity of coughing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Antitussive (drug class).